IGF-1 LR3
Animal pharmacology · No established human dosing schedule
IGF-1 LR3 is a modified growth-factor research reagent. Approved mecasermin instructions do not apply to this analogue. Animal pharmacology · No established human dosing schedule.
Reviewed 2026-10-17. A source reference, not a personal treatment plan. Discuss treatment decisions with a qualified clinician.
Dose reference
| STUDY CONTEXT | Dose | Frequency | Context |
|---|---|---|---|
| Human dosing | Not established | No validated schedule | No human dose follows from animal exposure or from an Increlex/mecasermin label. Changes in glucose are a material concern, not a reason to infer a starting amount. Source |
No human dose follows from animal exposure or from an Increlex/mecasermin label. Changes in glucose are a material concern, not a reason to infer a starting amount.
Source context
The cited rat work investigates the clearance and distribution of LR3IGF-I. Its altered binding behaviour is precisely why results for ordinary IGF-I do not make the analogue interchangeable.
Reading the dose correctly
No human dose follows from animal exposure or from an Increlex/mecasermin label. Changes in glucose are a material concern, not a reason to infer a starting amount.
Download the chart
Further reading
IGF-1 LR3 monograph on myPeptides
References
Why is there no numerical dose for IGF-1 LR3 on this card?
No human dose follows from animal exposure or from an Increlex/mecasermin label. Changes in glucose are a material concern, not a reason to infer a starting amount.
Does a missing dose mean that no research exists?
This card describes animal pharmacology. Evidence of a mechanism, a laboratory finding or an exposure does not by itself establish a useful and safe human treatment schedule. The monograph explains the distinction.